• summary
• income statement
• balance sheet
• cash flow
• other data

Get all company financials in excel:

Download Sample   $19.99

More Charts

Krka dd Novo Mesto is a Slovenia-based company involved in the production and sale of prescription pharmaceuticals, non-prescription products and animal health products. The Company operates through four segments: Prescription Pharmaceuticals that includes medicines for the treatment of cardiovascular diseases, alimentary tract and metabolism and drugs for diseases of the central nervous system, among others; Non-prescription Products, providing vitamins and minerals, cough and cold products, analgesics, sore throat products, among others; Animal Health Products, which offers general anti-infectives and antiparasitics for animals; Health Resort and Tourist Services. Krka sells approximately 92% of its products in more than 70 countries worldwide, mainly in Central and Eastern Europe

Finance

Krka has been growing its sales by a year on average in the last 5 years. EBITDA has grown on average by 0.96% a year during that time to total of EUR 307 mil in 2015, or 26.3% of sales. That’s compared to 27.4% average margin seen in last five years.

The company netted EUR 158 mil in 2015 implying ROE of 11.5% and ROCE of 9.90%. Again, the average figures were 13.1% and 11.0%, respectively when looking at the previous 5 years.

Krka’s net debt amounted to EUR -35.8 mil at the end of 2015, or -0.025 of equity. When compared to EBITDA, net debt was -0.117x, down when compared to average of -0.022x seen in the last 5 years.

Valuation

Krka stock traded at EUR 65.2 per share at the end of 2015 resulting in a market capitalization of USD 2,588 mil. Over the previous five years, stock price grew by 3.57% or 0.705% a year on average. The closing price put stock at a 12-month trailing EV/EBITDA of 6.44x and price to earnings (PE) of 13.5x as of 2015.